Articles
Value, big data and adaptation: the story of pharma in 2012

Value, big data and adaptation: the story of pharma in 2012

This year’s FT Global Pharmaceutical and Biotechnology conference focussed on value, big data, R&D innovation and adaptation for pharma, as Paul Tunnah explains. Attending the FT Global Pharmaceutical and Biotechnology conference last week it was fairly easy to tell what is keeping senior pharma execs awake at night…

Articles
Slow e-motion; big things and manners in internet health debates

Slow e-motion; big things and manners in internet health deb...

Nick Broughton reflects on last month’s debate with Ben Goldacre and shares his thoughts on why it’s important to keep good manners during discussions on social media. One of the more hefty crosses yours truly has to bear at the moment is a grimly devout loyalty to...

Articles
Data protection fines: enhancing patient protection or reducing treatments?

Data protection fines: enhancing patient protection or reduc...

Paul Gershlick discusses data protection fines in the UK and questions whether, with tightening healthcare budgets, they truly benefit the patient. At the beginning of 2012, the Information Commissioner’s Office (the “ICO”) announced that the health sector would be topping…

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D